REI Trials

European and Israeli Trials: HP-hMG vs recombinant FSH in IVF/ICSI (EISG and MERIT datasets)

  • Study design and scope

    • Type: Multinational, open-label, randomized, parallel-group, phase III trials; noninferiority framework for primary outcome in several analyses.

    • Settings: 22 centers across Belgium, Germany, Israel, The Netherlands, Switzerland, United Kingdom; later integrated across additional European centers for MERIT analysis.

    • Trials involved two gonadotropin preparations:

    • Highly purified hMG (HP-hMG, Menopur) containing FSH and LH activity (via HCG-driven LH activity)

    • Recombinant FSH (rFSH, follitropin alfa)

    • Key trials and design notes:

    • EISG trial (2002): HP-hMG vs recombinant FSH; large, noninferiority design with ongoing pregnancy rate as primary endpoint; randomization occurred before down-regulation; IVF/ICSI cycles; 731 randomized (APT/PP populations described separately).

    • MERIT trial (2006): Large assessor-blind randomized trial in a similar population; post-randomization exposure to gonadotropins; designed as superiority with possible noninferiority consideration; heavy emphasis on ongoing pregnancy as primary endpoint in original design; integration with EISG data performed subsequently.

    • Primary endpoint common to these analyses: ongoing pregnancy rate following one IVF/ICSI cycle (clinical pregnancy confirmed by ultrasound at ~10 weeks post-egg retrieval).

    • Key noninferiority/superiority thresholds:

    • EISG MERIT analyses used a noninferiority margin of about
      ext{Lower CI of difference} > -0.10
      (i.e., HP-hMG should be no worse than recombinant FSH by more than 10 percentage points in ongoing pregnancy rate).

    • MERIT integrated analysis later used different framing (live birth and ongoing pregnancy as endpoints) and reported noninferiority margins consistent with study design conventions of that project.

  • Inclusion/exclusion criteria (highlights)

    • Age: typically 18–38 years (EISGMERIT cohorts varied slightly in exact ranges across centers).

    • Infertility duration and cause: diverse etiologies (male factor, tubal factors, unexplained, endometriosis I/II in some cohorts).

    • BMI: generally within 18–29 kg/m² (with site-specific allowances).

    • Regular cycles with down-regulation using a long GnRH agonist protocol prior to stimulation.

    • Baseline reproductive hormones within normal ranges; estradiol <200–>1000 pmol/L at certain milestones for stimulation eligibility.

    • Exclusions included significant systemic disease, ovarian cysts, contraindications to gonadotropins, poor responder definitions, OHSS history, heavy smoking/alcohol use, and recent participation in other trials.

  • Stimulation protocol and dosing (common aspects across trials)

    • GnRH agonist down-regulation: long protocol (e.g., triptorelin 0.1 mg/day or depot formulations) started in midluteal phase; down-regulation confirmed by ultrasound/endocrine parameters before stimulation.

    • Start of stimulation: fixed dose of either HP-hMG or rFSH at 225extIU225 ext{ IU} daily for the first 5 days (visit 3).

    • Dose adjustment: on day 6, dose could be increased up to a maximum of 450extIU/day450 ext{ IU/day} (≈6 vials) or adjusted downward; adjustments allowed every ~4 days.

    • Criteria for oocyte maturation trigger: three follicles ≥16–17 mm and/or estradiol thresholds; trigger with hCG 5000–10,000 IU (or recombinant hCG in later/alternative protocols).

    • Oocytes retrieved ~36 hours after hCG; fertilization by standard IVF or ICSI per center practice.

    • Embryo transfer: typically 1–3 embryos transferred in various trials; single-embryo transfer emphasized in some later antagonist-cycle studies (e.g., MEGASET).

    • Luteal support: progesterone with local practice (e.g., vaginal progesterone 90 mg/day).

    • Cryopreservation: available for surplus good-quality embryos; some trials include frozen Embryo Transfer (FET) cycles within a year post-randomization.

  • Primary and secondary endpoints (highlights)

    • Primary efficacy endpoint: ongoing pregnancy rate per completed IVF/ICSI cycle (PP for primary noninferiority analyses; ITT used for safety analyses in MERIT-type designs).

    • Secondary efficacy endpoints: biochemical pregnancy (hCG positive), clinical pregnancy (ultrasound confirmation), number of follicles, number of oocytes retrieved, fertilization rates, number of embryos transferred, estradiol levels (on days 3/6 and day of hCG), endometrial status (thickness and echogenicity), days of stimulation, and number of vials used.

    • Safety endpoints: adverse events by system, frequency and severity of OHSS (type 2/3), miscarriages, multiple gestations, injection-site reactions; tolerability diaries for injection-site events.

  • Key results: ongoing pregnancy and safety (EISG/ MERIT era)

    • Ongoing pregnancy (PP population, per completed cycle): HP-hMG 25% (n ≈ 85/344) vs rFSH 22% (n ≈ 71/317); difference ≈ +2.62% (P ≈ 0.17). Lower CI limit ≥ -10% confirmed noninferiority.

    • Ongoing pregnancy per embryo transferred (to assess implantation success): similar noninferiority tendencies; overall, noninferiority of HP-hMG was confirmed in APT population for various end-points.

    • Biochemical and clinical pregnancies tended to be higher with HP-hMG but differences often not statistically significant.

    • Endocrine and follicular response differences:

    • Estradiol on the day of hCG: statistically higher with HP-hMG; estradiol concentration difference between HP-hMG and rFSH was significant (ΔE2 ≈ 1265 pmol/L; 95% CI 680–1864; P < 0.001).

    • Total follicles and follicle sizes: on day end of stimulation, rFSH produced more total follicles and more follicles ≥10 mm; however, estradiol and progesterone dynamics differed (see below).

    • Progesterone end-of-stimulation: higher with rFSH (P < 0.001).

    • Endometrial echogenicity: rFSH group showed a shift toward hyperechogenic endometrium more often than HP-hMG (P = 0.023).

    • Fertilization and embryo transfer metrics (PP population): similar fertilization rates and number of embryos transferred; HP-hMG often produced a higher proportion of top-quality embryos per retrieval in some analyses.

    • Safety: OHSS rates were low and similar overall; rare OHSS events occurred with both treatments; injection-site tolerability was similar across groups.

    • Live birth and total cycle outcomes (integrated MERIT analysis): live birth per started cycle in the fresh cycle tended to favor HP-hMG (e.g., 26% vs 21% in one analysis, OR ≈ 1.36; P ≈ 0.041 for live birth per cycle initiated in MERIT). Overall cumulative live birth rates with fresh and frozen cycles tended to be similar across HP-hMG and rFSH arms in some analyses, depending on the data subset and inclusion criteria.

    • Embryo quality and implantation: in MERIT-related embryo quality analyses, HP-hMG often yielded a higher proportion of top-quality embryos; top-quality embryos from HP-hMG were more likely to implant and lead to ongoing pregnancy and live birth in some sub-analyses.

  • Embryo quality-focused findings (MERIT-related studies)

    • Local vs central embryo assessment (MERIT-associated analyses, Ziebe et al.):

    • Top-quality embryos per oocyte retrieved (local): HP-hMG 11.3% vs rFSH 9.0%; P = 0.044.

    • Central review showed a non-significant difference (9.5% vs 8.0%).

    • Consolidated score: HP-hMG 48% vs rFSH 44% had top-quality embryos across patients.

    • Embryo quality parameters (DAY 2 vs DAY 3): HP-hMG associated with higher cell number and lower fragmentation on day 2/3 in some analyses; fragmentation >20% more common in HP-hMG but not consistently associated with worse outcomes across all endpoints.

    • Embryo transfer outcomes with top-quality embryos: when only top-quality embryos were transferred, live birth and ongoing pregnancy rates tended to be higher for HP-hMG (e.g., live birth 48% vs 32%; ongoing pregnancy 48% vs 32%; ongoing implantation 41% vs 27%), though statistical significance varied by analysis and central vs local scoring.

    • Cryopreservation: similar 1-year cryo-survival metrics; higher proportion of blastomeres surviving thaw in HP-hMG and higher resumption of mitosis after thaw in HP-hMG–derived embryos in some analyses.

  • MEGASET trial: GnRH antagonist cycle with compulsory single-blastocyst transfer (Fertil Steril 2012)

    • Design: randomized, open-label, assessor-blind, multicenter; comparison of HP-hMG (Menopur) vs rFSH (Gonal-F) in a GnRH antagonist COS cycle; compulsory single-blastocyst transfer on day 5; some cycles allowed subsequent frozen blastocyst transfers within 1 year.

    • Primary endpoint: ongoing pregnancy rate per started cycle (fresh cycle).

    • Key results (fresh cycle): ongoing pregnancy rate per started cycle 30% for HP-hMG vs 27% for rFSH in PP; 29% vs 27% in ITT; noninferiority established (lower limit of 95% CI above -12% margin).

    • Live birth: fresh cycle live birth rate 52.2% for HP-hMG vs 48.7% for rFSH; frozen cycle live birth rate 63.4% vs 50.8%; both cycles contributed to cumulative live birth rate: 50.6% for HP-hMG vs 51.5% for rFSH (cumulative across fresh+frozen within 1 year).

    • Embryo transfer and blastocyst data: mean embryos transferred per cycle ~1.7; most transfers were single; 82% of randomized patients underwent embryo transfer in the study; higher proportion of single transfers when comparing across arms due to policy and clinical practice.

    • OHSS safety: OHSS incidence lower with HP-hMG (approximately 9.7%) than with rFSH (≈21.4%), a notable safety difference; early OHSS rates also lower with HP-hMG (≈6.1% vs ≈17.5%).

    • Cumulative outcomes: despite more transfers in the rFSH arm, cumulative live birth rates were very similar between arms; the study supports noninferiority and favorable safety with HP-hMG.

    • Neonatal outcomes: overall neonatal health similar across arms; monozygotic twinning observed but in line with expected rates for blastocyst transfers.

    • Interpretive conclusions: HP-hMG yields comparable efficacy with a favorable safety profile (lower OHSS, reduced pregnancy losses), suggesting a favorable risk/benefit balance for HP-hMG in GnRH antagonist cycles with single-embryo transfers; differences in ovarian response and endometrial parameters were observed and discussed.

  • MEGASET-HR trial: high responders (Fertil Steril 2020)

    • Design: randomized, open-label, assessor-blind, multicenter trial in the U.S. (MEGASET-HR); included women predicted as high responders (AMH-based criteria: AMH ≥5 ng/mL) undergoing COS; HP-hMG vs rFSH + rLH combination (fixed-dose 2:1 ratio; HP-hMG equivalent vs rFSH with LH supplementation).

    • Primary endpoint: ongoing pregnancy rate per cycle start after fresh transfer.

    • Baseline and eligibility: AMH-based high-responder identification; AMH measured centrally; Bologna/POR-like criteria applied for risk stratification; inclusion criteria were designed to reflect high responder populations.

    • Treatment regimens: HP-hMG vs rFSH+rLH with GnRH antagonist coadministration; baseline dose was 150 IU/day for initial days (adjustments allowed); GnRH antagonist used to prevent premature LH surge.

    • Outcomes (fresh cycle): ongoing pregnancy rate per cycle start 35.5% for HP-hMG vs 30.7% for rFSH; noninferiority demonstrated (1-sided p-value, margin pre-specified); written as noninferiority with a lower bound exceeding the pre-specified margin.

    • Cumulative live birth outcomes: cumulative live birth rate per patient over a year (including frozen cycles) 40% for HP-hMG and 38% for rFSH; results are reported with 95% CIs around the differences; no significant superiority for HP-hMG over rFSH; the study supports a comparable performance with potential safety advantages for HP-hMG.

    • Pharmacodynamics and safety: notable differences in pharmacodynamics observed (e.g., LH exposure with LH-containing regimens); OHSS rates were lower with HP-hMG; endometrial and embryonic development metrics suggested differential influences on endometrial receptivity and embryo development, though primary outcomes were noninferior.

    • Safety and tolerability: TEAEs occurred but did not reveal major safety concerns; OHSS incidence was lower with HP-hMG; injection-site tolerability and other adverse events were similar across arms.

  • Mechanistic and practical implications

    • LH activity appears to modulate folliculogenesis, oocyte maturation, and endometrial receptivity; HP-hMG provides FSH activity plus LH activity via HCG-derived LH activity.

    • Higher estradiol levels with HP-hMG at the time of hCG trigger may reflect LH-driven steroidogenesis leading to endometrial enhancement; however, elevated progesterone late in stimulation (end-of-stimulation) was more associated with rFSH, potentially affecting endometrial timing and implantation in some cycles.

    • Endometrial echogenicity shifts toward hyperechogenic patterns with rFSH, which has been associated with poorer implantation in some contexts; HP-hMG tended toward more favorable endometrial patterns in certain analyses.

    • Embryo quality: HP-hMG tended to produce a higher proportion of top-quality embryos in some embryo assessments, and top-quality embryos from HP-hMG transfers showed higher implantation and live birth rates in selected analyses.

    • Oocyte yield vs embryo yield: rFSH often yielded more oocytes, but quality and implantation potential were not necessarily superior; HP-hMG’s LH activity may enhance oocyte/embryo quality and endometrial receptivity, contributing to higher ongoing pregnancy and live birth in some circumstances.

  • Key numerical highlights and formulas ( LaTeX-formatted)

    • Primary endpoints and noninferiority concepts:

    • Ongoing pregnancy rate per cycle: HP-hMG − rFSH =
      extDifference=0.250.22=0.03ext(PP)ext{Difference} = 0.25 - 0.22 = 0.03 ext{ (PP)}
      with a 95% CI lower bound above
      0.10-0.10, establishing noninferiority.

    • Endocrine and follicular metrics (examples):

    • Estradiol on day of hCG: ext{E}2^{ ext{hCG, HP-hMG}} - ext{E}2^{ ext{hCG, rFSH}} = 1265 ext{ pmol/L} ext{ (95% CI: 680–1864)}
      (P < 0.001).

    • Progesterone end of stimulation: P{ ext{end}}^{ ext{HP-hMG}} e P{ ext{end}}^{ ext{rFSH}} ext{ with } P < 0.001.

    • OHSS incidence (safety):

    • HP-hMG OHSS (types 2/3) ≈ 7/344 ext{ (1.9%)} vs recombinant FSH 4/317 ext{ (1.2%)} in the EISG PP dataset.

    • Live birth and ongoing pregnancy (MERIT integrated data):

    • Live birth rate per cycle initiated (fresh cycles): HP-hMG extLBRextfresh=0.265ext{LBR}_{ ext{fresh}} = 0.265 vs rFSH 0.2080.208; OR ≈ 1.36 ext{ (95% CI: 1.01–1.83)}; P = 0.041.

    • Ongoing pregnancy rate per started cycle (fresh): HP-hMG 0.270extvs0.2200.270 ext{ vs } 0.220; OR ≈ 1.38 (95% CI around 1.03–1.86).

    • Cumulative live birth rate per patient (fresh+frozen within 1 year): HP-hMG ≈ 0.5060.506 vs rFSH ≈ 0.5150.515; difference ≈ 0.8extpercentagepoints-0.8 ext{ percentage points}; 95% CI around difference broad, includes 0.

    • Embryo-quality-related metrics (MERIT):

    • Top-quality embryos per oocytes retrieved (local): HP-hMG 11.3 ext{%} vs rFSH 9.0 ext{%}; P = 0.044.

    • Central scoring showed a similar directional trend but with non-significant difference.

  • Conclusions and practical implications

    • Across major RCTs and integrated analyses, HP-hMG is at least as effective as recombinant FSH for COS in IVF/ICSI under long GnRH agonist protocols, with certain studies showing a trend toward higher ongoing pregnancy and live birth rates when HP-hMG is used, particularly in IVF cycles with LH activity from the start of stimulation.

    • HP-hMG generally demonstrates a more favorable or comparable safety profile, notably with lower OHSS incidence in several trials.

    • In antagonist-cycle trials with single-blastocyst transfer (MEGASET), HP-hMG maintained noninferiority to rFSH for ongoing pregnancy and showed lower OHSS and pregnancy loss, with cumulative live birth rates that were similar between arms.

    • In high-responder populations (MEGASET-HR), HP-hMG demonstrated noninferiority for ongoing pregnancy, with safety advantages (lower OHSS) and potential implications for personalized stimulation strategies based on biomarkers like AMH.

    • Overall, HP-hMG provides an attractive alternative to rFSH, offering a biologically balanced LH/FSH activity profile, potential endometrial and embryonic quality advantages, and favorable safety considerations, particularly in IVF cycles employing LH-active gonadotropins from cycle start.

  • Connections to broader ART principles and ethical/practical considerations

    • Personalization of COS: AMH-based identification of high responders was explored (MEGASET-HR) to tailor stimulation intensity and reduce OHSS risk, illustrating a move toward individualized ART regimens.

    • Embryo transfer strategy: several trials emphasize single-embryo transfer or blastocyst-stage transfers to optimize live birth rates while minimizing multiple gestations; results interact with direct gonadotropin choice by influencing embryo quality and endometrial receptivity.

    • Economic and health implications: noninferiority plus safety advantages can translate into cost-savings and reduced maternal-fetal risk; meta-analyses and subsequent economic evaluations have supported HP-hMG as a cost-effective alternative in many practice settings.

    • Ethical considerations: the balance between maximizing live birth rates and minimizing OHSS and pregnancy-related complications remains central; trials increasingly probe not just pregnancy rates but cumulative outcomes and neonatal safety across fresh and frozen cycles.

  • Takeaway for exam-ready understanding

    • HP-hMG (FSH + LH activity) often matches or modestly exceeds rFSH in ongoing pregnancy and live birth outcomes, especially in IVF cycles with long down-regulation or antagonist protocols where LH activity may influence follicular development, oocyte/embryo quality, and endometrial receptivity.

    • Across multiple large RCTs and integrated analyses, HP-hMG tends to reduce OHSS risk and may improve certain embryo-quality metrics, though findings can vary by study design and endpoint definitions.

    • The landscape supports a role for LH-active gonadotropins in specific IVF contexts, with HP-hMG offering a practical, cost-effective option that can align with patient-specific risk profiles and transfer policies.